Assessing New Therapies for Retinal Diseases

Opinion
Video

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.

Video content above is prompted by the following:

  • New Therapies:
  • Aflibercept 8 mg
Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
3 experts are featured in this series.
Related Content
Rows of medical syringes in sanitary packaging. Concept image for aflibercept intravitreal eye injection. ©Titolino – stock.adobe.com

Study examines real-world treat-and-extend outcomes and background factors of macular atrophy

Lynda Charters
March 21st 2025
Article

The study demonstrated that the number of injections needed gradually decreased during the follow-up period

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A person in scrubs holds their hand outstretched toward the camera. A digital overlay gives the impression that the doctor or clinician is offering information about the future of eye care and retinal health. Image credit: ©sdecoret – stock.adobe.com

Advanced therapies in neovascular AMD and DMO: Experts weigh in

Hattie Hayes
March 12th 2025
Article

A clinician panel illuminates current treatment paradigms and best practices for reducing treatment burden

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An illustration of kidneys, in black-and-white, with color over some sections to indicate disease. Image credit: ©Crystal light – stock.adobe.com

EMA validates indication extension application of pegcetacoplan for treatment of kidney disease

Hattie Hayes
February 20th 2025
Article

According to Apellis and Sobi, pegcetacoplan (Aspaveli) first received marketing authorisation for treatment of paroxysmal nocturnal hemoglobinuria

A doctor in a white coat and a nurse in teal scrubs shake hands. Image credit: ©master1305 – stock.adobe.com

SpaMedica and Vision Express partner for UK training placement programme

Jordana Joy
February 18th 2025
Article

The partnership with the NHS eye patient servicer will help preregistration optometrists access training in community and hospital settings

© 2025 MJH Life Sciences

All rights reserved.